The strategic objective of Prot-HiSPRA is to reach an effective integration of proteome related measurements with on-line sample preparation (depletion, digestion, fractionation), hyphenated data collection, including high resolution separation based on nano-High Performance Liquid Chromatography (nano HPLC), and mass spectrometry (MS), as well as fast and reliable data analysis using intelligent correlation of HPLC and MS results. (read more...)
Glycosylation is a post-translational modification that enriches protein complexity and function. Dysregulation of glycosylation is associated with a wide range of diseases, including cancer, diabetes, as well as congenital, cardiovascular, immunological and infectious disorders. A number of studies identified potentially important glycan disease biomarkers. With regard to biotechnology, proper glycosylation of biologicals is important, as deviations in glycosylation are known to be associated with adverse drug reactions and reduced therapeutic efficacy. However, glycomics is significantly lagging behind genomics and proteomics, mainly due to the absence of high-throughput analytical methods which can reliably quantify a multitude of glycan structures in complex biological samples. (read more...)
The main aim of the HTP-GlycoMet proposal is to develop technologies, which will enable high-throughput analysis of glycosylation of individual proteins from body fluids and cell membranes and apply them to understand some key processes in immunity and infections. By successfully combining complementary expertise in the (i) production of specialised monolithic chromatographic tools for high-throughput fractionation of complex biological fluids, (ii) purification of proteins from body fluids and membrane proteins, (iii) high-throughput glycomic analysis by use of chromatography and multiplexed capillary gel electrophoresis and (iv) expertise in the field of viral immunology the consortium aims to achieve significant progress in this direction.
The Intenso project is about identifying the bottlenecks of the currently used downstream processing methods, and finding new solutions to circumvent them. This is highly relevant for any and all biotechnical products, as downstream processes account for more than 80% of the manufacturing costs. The Intenso approach will not concentrate solely on the effectiveness of the new methods, but will strive to lead to a sustainable approach, factoring in risk management derived from economic, environmental, and social developments, also including government policies and legal constraints. (read more...)